APA

Wysham C., Bonadonna R. C., Aroda V. R., Puig Domingo M., Kapitza C., Stager W., Yu C., Niemoeller E., Souhami E. & Bergenstal R. M. (20180712). Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. : Diabetes, obesity & metabolism.

Chicago

Wysham Carol, Bonadonna Riccardo C, Aroda Vanita R, Puig Domingo Manuel, Kapitza Christoph, Stager William, Yu Christine, Niemoeller Elisabeth, Souhami Elisabeth and Bergenstal Richard M. 20180712. Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. : Diabetes, obesity & metabolism.

Harvard

Wysham C., Bonadonna R. C., Aroda V. R., Puig Domingo M., Kapitza C., Stager W., Yu C., Niemoeller E., Souhami E. and Bergenstal R. M. (20180712). Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. : Diabetes, obesity & metabolism.

MLA

Wysham Carol, Bonadonna Riccardo C, Aroda Vanita R, Puig Domingo Manuel, Kapitza Christoph, Stager William, Yu Christine, Niemoeller Elisabeth, Souhami Elisabeth and Bergenstal Richard M. Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. : Diabetes, obesity & metabolism. 20180712.